

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **SHANGHAI JUNSHI BIOSCIENCES CO., LTD.\***

### **上海君實生物醫藥科技股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 1877)**

## **OVERSEAS REGULATORY ANNOUNCEMENT**

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Reference is made to “Shanghai Junshi Biosciences Co., Ltd.: Announcement on Correction of 2018 Annual Report” dated 13 December 2019 published by Shanghai Junshi Biosciences Co., Ltd. (the “**Company**”) on the website of the National Equities Exchange and Quotations. The following is a translation of the official announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

The corrections/adjustments are made on the Company's financial statements prepared under the China Accounting Standards (PRC GAAP) as published on the website of the National Equities Exchange and Quotations in relation to the financial year ended 31 December 2018. The corrections/adjustments do not affect the Company's relevant financial statements prepared under the International Financial Reporting Standards (IFRSs) as published on the website of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with respect to the corresponding period.

The corrections/adjustments are related to a money receipt and return which took place prior to the listing of the Company's H shares on the Stock Exchange on 24 December 2018 (the “**Listing**”). To the best knowledge, information and belief of the Company having made all reasonable enquiries, Beijing Baiyining Medical Technology Co., Ltd.\* (北京百益寧醫學科技有限責任公司) is not a connected person (as defined in the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”)) of the Company. The money receipt and return did not constitute a connected transaction of the Company under Chapter 14A of the Listing Rules.

By Order of the Board  
**Shanghai Junshi Biosciences Co., Ltd.\***  
**Mr. Xiong Jun**  
*Chairman*

Shanghai, the PRC, 13 December 2019

*As at the date of this announcement, the board of directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Feng Hui, Mr. Zhang Zhuobing, Dr. Wu Hai and Dr. Yao Sheng as executive directors; Mr. Tang Yi, Mr. Li Cong, Mr. Yi Qingqing and Mr. Lin Lijun as non-executive directors; and Dr. Chen Lieping, Dr. He Jia, Mr. Chen Xinjun, Mr. Qian Zhi and Dr. Roy Steven Herbst as independent non-executive directors.*

\* For identification purpose only

Stock Code:833330 Stock Short Name: Junshi Bio-B Chief Agency Broker:  
CICC

**Shanghai Junshi Biosciences Co., Ltd.\***

上海君實生物醫藥科技股份有限公司

**Announcement on Correction of 2018 Annual Report**

The Company and all members of the Board of Directors warrant that the contents of the announcement are true, accurate and complete and that there is no false and misleading statement or material omission herein, and are severally and jointly responsible for the truthfulness, accuracy and completeness of the contents herein.

Shanghai Junshi Biosciences Co., Ltd. (hereinafter referred to as the “Company”) published the 2018 Annual Report of Shanghai Junshi Biosciences Co., Ltd. (After Correction) (Announcement No.: 2018-133)(《上海君實生物醫藥科技股份有限公司2018 年年度報告(更正後)》(公告編號:2018-133)) on the website of the National Equities Exchange and Quotations (www.neeq.com.cn) on 25 September 2019. On 12 December 2019, the Resolution on Correction of Accounting Errors in Prior Years (《關於公司前期會計差錯更正的議案》) was considered and approved at the 18th meeting of the second session of the Board of Directors and the 15th meeting of the second session of the Supervisory Committee of the Company. Pursuant to which, the Company made corrections to the 2018 annual report as follows:

**I. Specific Contents and Reasons for Corrections**

**Before correction:**

**Section V Significant Matters**

**II. Details of Significant Matters (If the matter exists, select the form below to fill out)**

**(ii) Incidental related party transactions of the Company during the reporting period**

Currency: RMB

Related party	Subject matter	Transaction amount	Whether perform necessary decision-making procedures	Disclosure time of temporary report	No. of temporary report
Shanghai Tanying Investment Partnership (LP) * (上海檀英投資合夥企業(有限合夥)), Beijing Baiyining Medical Technology Co., Ltd. * (北京百益寧醫學科技有限責任公司), Shanghai Qiangang Investment Management Partnership (LP) * (上海乾剛投資管理合夥企業(有限合夥))	Establishment of a company with related parties	3,000,000.00	Have performed timely before the transaction	12 September 2018	2018-151

**Notes to Financial Statement:****X. Related Party and Related Party Transaction**

**7. Related Party Transaction**

- (1) Related party transactions for the purchase and sale of goods, provision and receiving of labour services

## Purchase of commodities and receiving labour services

Related party	Subject matter	Transaction amount for the current period	Transaction amount for the previous period
Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd. * (軍科正源（北京）藥物研究有限責任公司)	Clinical and technical service fee	10,114,898.12	7,611,320.76
Beijing Zhengdan International Technology Co., Ltd. * (北京正旦國際科技有限責任公司)	Technical service fee	226,415.09	339,622.63
Jiangsu Ruihe Environmental Engineering Research Centre Co., Ltd. * (江蘇瑞河環境工程研究院有限公司)	Wastewater testing fee	5,188.68	—
Jiangsu Ruihe Environmental Engineering Research Centre Co., Ltd. * (江蘇瑞河環境工程研究院有限公司)	Consultation service fee	—	1,132,075.48
Huimei Medical Management	Technical service fee	—	7,617,475.75

Consultancy (Beijing) Co., Ltd. * (惠每醫療管理諮詢（北京）有限公司)			
------------------------------------------------------	--	--	--

## Sales of commodities and provision of labour services

Related party	Subject matter	Transaction amount for the current period	Transaction amount for the previous period
Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd. * (軍科正源（北京）藥物研究有限責任公司)	Reagent sales	104,933.85	793,274.18
Beijing Zhengdan International Technology Co., Ltd. * (北京正旦國際科技有限責任公司)	Reagent sales	140,992.74	317,013.68
Beijing Junke Huaren Pharma Tech Co., Ltd. * (北京軍科華仞生物工程技術研究有限公司)	Reagent sales	1,786.33	406,188.03

## (2) Key management personnel compensation

Item	Transaction amount for the current period	Transaction amount for the previous period
Key management personnel compensation	19,470,453.78	10,212,321.68

## II. Specific Contents After Correction

After correction:

## Section V Significant Matters

## II. Details of Significant Matters (If the matter exists, select the form below to fill out)

## (ii) Incidental related party transactions of the Company during the reporting period

Currency: RMB

Related party	Subject matter	Transaction amount	Whether perform necessary decision-making procedures	Disclosure time of temporary report	No. of temporary report
Shanghai Tanying Investment Partnership (LP) * (上海檀英投資合夥企業(有限合夥)), Beijing Baiyining Medical Technology Co., Ltd. * (北京百益寧醫學科技有限責任公司), Shanghai Qiangang Investment Management Partnership (LP) * (上海乾	Establishment of a company with related parties	3,000,000.00	Have performed timely before the transaction	12 September 2018	2018-151

剛投資管理合 夥企業(有限合 夥))					
Beijing Baiyining Medical Technology Co., Ltd. * (北 京百益寧醫學 科技有限責任 公司)	Money received and returned	10,000,000.00	Had performed retrospecti vely after the transaction	13 December 2019	2019-167

**Notes to Financial Statement:****X. Related Party and Related Party Transaction****7. Related Party Transaction**

- (1) Related party transactions for the purchase and sale of goods, provision and receiving of labour services

Purchase of commodities and receiving labour services

Related party	Subject matter	Transaction amount for the current period	Transaction amount for the previous period
Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd. * (軍科正源(北 京)藥物研究有限責任公 司)	Clinical and technical service fee	10,114,898.12	7,611,320.76
Beijing Zhengdan International Technology	Technical service fee	226,415.09	339,622.63

Co., Ltd. * (北京正旦國際科技有限責任公司)			
Jiangsu Ruihe Environmental Engineering Research Centre Co., Ltd. * (江蘇瑞河環境工程研究院有限公司)	Wastewater testing fee	5,188.68	—
Jiangsu Ruihe Environmental Engineering Research Centre Co., Ltd. * (江蘇瑞河環境工程研究院有限公司)	Consultation service fee	—	1,132,075.48
Huimei Medical Management Consultancy (Beijing) Co., Ltd. * (惠每醫療管理諮詢（北京）有限公司)	Technical service fee	—	7,617,475.75

## Sales of commodities and provision of labour services

Related party	Subject matter	Transaction amount for the current period	Transaction amount for the previous period
Junke Zhengyuan (Beijing) Pharmaceutical Research Co., Ltd. * (軍科正源（北京）藥物研究有限責任公司)	Reagent sales	104,933.85	793,274.18



Beijing Zhengdan International Technology Co., Ltd. * (北京正旦國際科技有限責任公司)	Reagent sales	140,992.74	317,013.68
Beijing Junke Huaren Pharma Tech Co., Ltd.* (北京軍科華仞生物工程技術研究有限公司)	Reagent sales	1,786.33	406,188.03

## (2) Key management personnel compensation

Item	Transaction amount for the current period	Transaction amount for the previous period
Key management personnel compensation	19,470,453.78	10,212,321.68

## (3) Money received and returned between related parties

Related party	Amount (Yuan)	Date of receipt	Date of return
Beijing Baiyining Medical Technology Co., Ltd.* (北京百益寧醫學科技有限責任公司)	10,000,000.00	18 October 2018	6 November 2018

**III. Other Explanations**

The Resolution on Correction of Accounting Errors in Prior Years (《關於公司前期會計差錯更正的議案》) was considered and approved at the 18th meeting of the second session of the Board of Directors and the 15th meeting of the second session of the Supervisory Committee of the Company. Except for the above corrections, the remaining contents of the 2018 Annual Report of Shanghai Junshi Biosciences Co., Ltd. (After Correction) (《上海君實生物醫藥科技股份有限公司 2018 年年度報告 (更正後)》) remains unchanged.

We apologize for the inconvenience caused by the above corrections to investors.

Announcement is hereby given.

Board of Directors of  
Shanghai Junshi Biosciences Co., Ltd.  
13 December 2019